Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …

Teriflunomide (Aubagio®) is a disease-modifying immunomodulatory drug with anti-
inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme …

(1) Background: Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune
disease. Fatigue is a prevalent and debilitating symptom that significantly impacts the quality …

BACKGROUND: Medication adherence is critical for the realization of pharmacotherapy
benefits and reduced healthcare expenditure. Studies have shown up to 60% of people with …

Background Though adherence to disease-modifying therapies (DMTs) among persons with
multiple sclerosis (PwMS) varies and is often below 80%, only few prospective studies on …

Background The introduction of oral disease-modifying therapies (DMTs) for relapsing–
remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment. Objectives To …

Background: Pathologic changes in cortical gray matter (GM) and leptomeninges contribute
to disability worsening in patients with multiple sclerosis (MS), but there is little evidence …

Aims: We aimed to examine the frequency of polypharmacy in a large cohort of patients at
the time of diagnosis of relapsing–remitting multiple sclerosis (RRMS) and to explore its …

The current study aims to compare injectable and oral first-line disease-modifying therapies
(DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to …